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Abstract
Chitosan can favorably modulate plasma lipids, but the available data are not conclusive. We evaluated the effect of chitosan on
plasma lipids and lipoproteins in 28 patients with plasma triglyceride levels >150 mg/dL (mean age: 63 + 12 years), not taking
other lipid-lowering agents. All patients received a chitosan derived from fungal mycelium (Xantonet, Bromatech, Italy) at a fixed
dose of 125 mg/d in addition to their current medications for 4 months. Polyacrylamide gel electrophoresis was used to measure
low-density lipoprotein (LDL) subclasses. After treatment, total cholesterol reduced by 8%, LDL cholesterol by 2%, and
triglycerides by 19%, with a concomitant 14% increase in high-density lipoprotein cholesterol. We also found a beneficial effect
of chitosan on LDL subclasses, with a significant increase in LDL-2 particles (from 37+ 8% to 47+ 8%, P¼ .0001) and a decrease
(although not significant) in atherogenic small, dense LDL. Whether these findings may affect cardiovascular risk remains to be
established in future studies.
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Introduction
Chitosan is a food supplement, and its positive anions are
thought to bind to negatively charged lipids from dietary fats,
preventing fat digestion and reducing fat storage.1,2 A further
proposed mechanism is through inhibition of pancreatic lipase
that is necessary for fat absorption, and several studies have
shown reduction in weight when chitosan is given with a low-
energy diet.3 Others have investigated whether chitosan may
be able to favorably modulate plasma lipids, and this is of inter-
est since natural products tend not to have major side effects.
Indeed, chitosan is a natural product that is, after cellulose, the
second more common biopolymer on the Earth.4 Although not
derived from plants, chitosan being a polysaccharide is similar
to a dietary fiber that is indigestible by mammalian digestive
enzymes. Chitosan is the deacetylated form of chitin, an aminopo-
lysaccharide found in the exoskeleton of arthropods and certain
fungi.5 There are no major side effects reported with the use of
chitosan, although it may cause mild stomach upset, constipation,
or gas.6 Among potential interactions, it should be highlighted
that chitosan may interact with warfarin, an anticoagulant.6
Available data on the role of chitosan on plasma lipids are not
conclusive. Several studies have shown that chitosan can reduce
total cholesterol levels in patients with hypercholesterolemia,7,8
and this has been confirmed in a meta-analysis of published
randomized controlled trials.9 In contrast, the effects of chitosan
in patients with hypertriglyceridemia are largely unknown
although in animal models fed with a high-fat diet chitosan was
able to decrease triglycerides by 29% to 31%, with a concomitant
increase in high-density lipoprotein cholesterol (HDL-C) by 8%
to 11%.10 This is consistent with the data published by Ausar
et al who reported an increase in HDL-C concentrations by chit-
osan in patients with dyslipidemia.7 Further, no study has so far
investigated the effects of chitosan on plasma lipoproteins. This
is also of potential importance, since increasing evidence suggests
that the ‘‘quality’’ and not only the ‘‘quantity’’ of plasma lipids
significantly influences the cardiovascular (CV) risk.11
The aim of the present study was to evaluate the effects of
chitosan on plasma lipids and lipoproteins in patients with
hypertriglyceridemia not taking other lipid-lowering agents.
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Materials and Methods
Patients and Methods
We studied 28 patients with hypertriglyceridemia (ie, plasma
triglyceride levels >150 mg/dL), 13 women and 15 men, with
a mean age of 63 + 12 years who were referred to our Unit
of Cardiovascular Prevention for a clinical evaluation. All
patients did not use lipid-lowering agents for at least 3 months
before entering the study, since they were statin-intolerant or
new patients. The project design included a medical examina-
tion, anthropometric data, biochemical analyses, and echo
color-Doppler examination of the carotid arteries. The proce-
dures adopted were in agreement with the Helsinki Declaration
of 1975 as revised in 1983 and were approved by the Ethics
Council of the University of Palermo.
All patients gave their informed consent to participate in the
study. On admission, they underwent a medical examination and
were excluded from the study if they had clinical evidence of
liver dysfunction or renal failure. Waist circumference, height,
and weight were recorded, and body mass index (BMI) was
calculated as kg/m2. Of the patients, 9 were current smokers,
23 had type-2 diabetes, and 18 had hypertension diagnosed by
the following systolic or diastolic blood pressure140 or 90
mm Hg , respectively, or previous pharmacological therapy with
antihypertensive drugs. In all, 23 patients were already taking
antihypertensive and/or antidiabetic drugs, and such medications
were maintained at the same doses until the end of the study.
Regarding antidiabetic drugs, all the 23 patients with type-2
diabetes received metformin therapy, while add-on therapy
included a glucagon-like peptide 1 (GLP-1) analog in 21
patients, a sulfonylurea in 6 patients, pioglitazone in 2 patients,
and insulin in 1 patient. Five patients had a previous CV event.
All patients received a chitosan derived from fungal mycelium
(Xantonet, Bromatech, Italy) at a fixed dose of 125 mg/d
(2 tablets/d) in addition to their current medication.
The presence of the metabolic syndrome was defined by the
joint American Heart Association/National Heart, Lung, and
Blood Institute Scientific Statement,12 that is, the presence of
any 3 of the following 5 risk factors: elevated waist circumfer-
ence (>88 cm in women and >102 cm in men), elevated fasting
triglycerides (150 mg/dL or on drug treatment for elevated
triglycerides), reduced HDL-C (<50 mg/dL in women and
<40 mg/dL in men or on drug treatment for reduced HDL-C),
elevated blood pressure (systolic blood pressure 130 mm
Hg or diastolic blood pressure 85 mm Hg or on antihyperten-
sive drug treatment in a patient with a history of hypertension),
and elevated fasting glucose (100 mg/dL or on drug treatment
for elevated glucose).
Biochemical Analyses
At baseline and after 4 months, serum parameters were measured
after a 14-hour overnight fast. Total cholesterol, triglycerides, and
HDL-C were measured by standard enzymatic-colorimetric
methods,13-15 while low-density lipoprotein cholesterol (LDL-C)
was calculated using the Friedewald formula.
Lipoprotein Subclass Analysis
Nondenaturing, linear polyacrylamide gel electrophoresis was
used to separate and measure LDL subclasses in a subset of
16 randomized samples, with the Lipoprint system16 (Quanti-
metrix Corporation, Redondo Beach, California). This method
has been validated against gradient gel electrophoresis and
nuclear magnetic resonance, and it is the only Food and Drug
Administration-cleared diagnostic tool for lipoprotein subfrac-
tion testing in the United States.17 The electrophoresed gels
were scanned to determine the relative area of each lipoprotein
subfraction. In detail,18 25 mL of the sample was mixed with
200 mL of Lipoprint loading gel and placed upon the upper part
of the 3% polyacrylamide gel. After 30 minutes of photopoly-
merization at room temperature, electrophoresis was performed
for 60 minutes with 3 mA for each gel tube. Each electrophor-
esis chamber involved 2 quality controls.
For quantification, scanning was performed with a digital
scanner and a Mac personal computer (Apple Computer Inc). AQ3
After scanning, the electrophoretic mobility and the area under
the curve were calculated. The LDL subclasses were distribu-
ted as 7 bands (LDL-1 to LDL-7, respectively): LDL-1 and
LDL-2 are defined as large LDL; LDL-3 to LDL-7 are defined
as small LDL.18
Statistical Analysis
Statistical analysis was performed using Statview 5.0 (SAS
Institute Inc, Cary, North Carolina). Univariate analysis was
performed using 2-tailed paired Student t tests, while correla-
tion analysis was performed using the Spearman rank correla-
tion method.
Results
In Table 1, we report the effects of the 4-month chitosan ther-
apy on BMI, waist circumference, and plasma lipids. The BMI
and waist circumference (in cm) were significantly reduced
after therapy (from 30 + 5 to 29 + 4, P ¼ .015 and from
104 + 14 to 102 + 12, P ¼ .032, respectively). Regarding
plasma lipids, total cholesterol and triglycerides were signifi-
cantly lowered (from 192 + 43 to 171 + 23, P ¼ .019 and
from 228 + 72 to 176 + 54 mg/dL, P < .001, respectively),
Table 1. Effects of 4-Month Chitosan Therapy on Body Mass Index
(BMI), Waist Circumference, and Plasma Lipids.
Before
Treatment P
After
Treatment
BMI, kg/m2 30+ 5 .015 29 + 4
Waist circumference, cm 104+ 14 .032 102 + 12
Total cholesterol, mg/dL 192+ 43 .019 171 + 23
Triglycerides, mg/dL 228+ 72 <.001 176 + 54
HDL-cholesterol, mg/dL 39+ 9 .016 44 + 10
LDL-cholesterol, mg/dL 107+ 44 NS 92 + 20
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein;
NS, not significant.
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while HDL-C significantly increased (from 39+ 9 to 44+ 10
mg/dL, P ¼ .016). The LDL-C levels also fell, but the differ-
ence did not reach significance (from 107 + 44 to 92 + 20
mg/dL). In addition, fasting plasma glucose and glycated
hemoglobin significantly fell after treatment (from 151 + 70
to 134 + 34 mg/dL, P ¼ .003 and from 8.4 + 1.2% to 7.0
+ 1.1%, P < .001, respectively), while the presence of the
metabolic syndrome decreased from 22 patients before chito-
san supplementation to 17 patients after treatment.
Table 2 shows the effects of chitosan on LDL size and sub-
classes. The only significant change was for LDL-2, which sig-
nificantly increased after treatment (from 37 + 8% to 47 +
8%, P < .001). Other LDL subclasses, including LDL-1,
LDL-3, LDL-4, and LDL-5, significantly decreased after treat-
ment, but the difference did not reach the significance. We also
report a slight but not significant increase in LDL peak particle
size (from 264 + 7 to 265 + 5 A˚). Spearman correlations
between treatment changes in BMI, waist circumference, and
plasma lipids and changes in LDL subclasses (see Table 3)
showed that the only correlation that reached the significance
was that between LDL-2 and triglycerides (r ¼ .456, P < .05).
Discussion
This is the first study that investigated the effects of chitosan on
lipoproteins. We found that after 4 months of therapy, total
cholesterol reduced by 8%, LDL-C by 2%, and triglycerides
by 19%, with a concomitant 14% increase in HDL-C. These
findings extend previous observations on the effects of chitosan
in reducing total cholesterol levels in patients with hypercho-
lesterolemia,5,6 as well as in increasing HDL-C concentrations
in patients with dyslipidemia.4 The most pronounced effects of
chitosan in the present study were found for triglycerides
(19%), and this was suggested in animal models fed a high-
fat diet, where this agent was able to decrease triglycerides
by 29% to 31%.10
Beyond plasma lipids concentrations, several expert panels
and international guidelines, such as the National Cholesterol
Education Program Adult Treatment Panel III, have accepted
the predominance of small, dense LDLs (sdLDLs) as an emer-
ging CV risk factor.19 Most studies suggest that measuring
LDL particle size, sdLDL cholesterol content, and LDL parti-
cle number provides additional assessment of CV risk.11 A Eur-
opean panel of experts recently provided a comprehensive
consensus statement on the pathophysiology, atherogenicity,
and clinical significance of LDL subclasses,17 and the main
findings are summarized in its executive statement.20
The LDLs comprise multiple subclasses with different size,
density, physicochemical composition, metabolic behavior,
and atherogenicity; based on their characteristic appearance
in analytical ultracentrifugation and gradient gel electrophor-
esis, up to 7 distinct LDL subclasses can be defined.17 In clin-
ical practice, LDL phenotype B refers to patients with a
predominance of sdLDL, meaning those with a predominance
of LDL-3 and LDL-4 subclasses.17 The magnitude and inde-
pendence of the association of LDL size with CV risk has been
tested in >100 studies, including cross-sectional and prospec-
tive epidemiologic as well as clinical intervention trials, and
the vast majority of these trials demonstrate a significant
association of sdLDL with increased CV risk.21
Several mechanisms have been suggested to explain the
enhanced atherogenicity of sdLDL. These particles are taken
up more easily by arterial tissue than larger counterparts, sug-
gesting greater transendothelial transport.22 In addition, sdLDL
have also decreased receptor-mediated uptake and increased
proteoglycan binding; further, sialic acid plays a role in the
in vitro association of LDL with the polyanionic proteoglycans,
and the sialic acid content of LDL particles in patients with a
predominance of sdLDL is reduced.23 It has also been shown
that oxidative susceptibility increases and antioxidant concen-
trations decrease with lowering LDL size.24
The present study shows for the first time a beneficial effect
of chitosan on LDL subclasses, with a significant increase in
less atherogenic LDL particles (eg, LDL-2 particles) and a con-
comitant decrease (although not significant) in atherogenic
sdLDL. It should be highlighted that correlation analysis
revealed that the reduction in LDL-2 was significantly corre-
lated with the decrease in plasma triglyceride levels. Therefore,
the triglyceride reduction induced by chitosan seems to have a
direct impact on the modulation of LDL subclasses, toward less
atherogenic particles.
Beyond the effects on plasma lipids and lipoproteins, in the
present study we have found a beneficial effect of chitosan on
weight loss, as reported previously.25 We cannot exclude a
potential action of this weight loss on the plasma lipid variables
measured, including triglycerides, HDL-C, and LDL subfrac-
tions, through amelioration of insulin resistance.16,26 Further,
glycemic indices improved, and fewer patients had the meta-
bolic syndrome after treatment; this is consistent with previous
findings on the potential effects of chitosan on adipokines and/
or nonalcoholic fatty liver disease (NAFLD), as discussed
below.
Chitosan has been previously shown to beneficially affect
insulin resistance (assessed by homeostasis model assessment
resistance index, plasma glucose, and GLP-1 levels) and fatty
liver (assessed by hepatic triglycerides and cholesterol content)
in animal studies27-29; both insulin resistance and NAFLD are
Table 2. Effects of 4-Month Chitosan Treatment on Low-density
Lipoproteins (LDL) Size and Subclasses.
Before
Treatment P
After
Treatment
LDL peak particle size, A˚ 264 + 7 NS 265 + 5
LDL-1, % 43 + 18 NS 38 + 14
LDL-2, % 37 + 8 .0001 47 + 8
LDL-3, % 15 + 11 NS 13 + 8
LDL-4, % 4 + 3 NS 2 + 1
LDL-5, % 1 + 2 NS 0 + 0
LDL-6, % 0 + 0 NS 0 + 0
LDL-7, % 0 + 0 NS 0 + 0
Abbreviation: NS, not significant.
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associated with increased vascular risk.30,31 Furthermore,
plasma adiponectin was increased, whereas plasma inflamma-
tory markers such as necrosis factor-a and interleukin 6 were
reduced following chitosan treatment.27,29 With regard to
leptin, chitosan has been reported to decrease circulating leptin
levels in animals with diet-induced obesity25 and nonalcoholic
steatohepatitis,29,32 both of which arecharacterized by hyper-
leptinemia.33 Such adipokines are associated with increased
vascular risk,34,35 and several drugs may affect their levels.36,37
Therefore, the clinical implications of chitosan effects on these
biochemical markers remain to be evaluated in future studies.
Yet, in our study, liver tests did not improve after chitosan
treatment (data not shown).
Potential limitations of our study include the relatively small
number of patients as well as the use of cardiometabolic med-
ications. Indeed, we cannot exclude the fact that the use of anti-
diabetic agents did not influence the results of this study; GLP-
1 analogswere widely used in the diabetic patientsincluded in
this study, and increasing evidence suggests nonglycemic
effects of these agents, including significant effects on weight
loss as well as plasma lipids and lipoproteins.38,39
In conclusion, in this pilot study we report significant bene-
ficial effects of chitosan on plasma lipids and lipoproteins after
4 months of treatment. Whether these findings may affect CV
risk remains to be established in the future studies.
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